Category: Epidarex Portfolio News
CHARLOTTESVILLE, Va. —Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology’s GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., management and others….
Oxford, UK, 7th January 2020 – Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $7 million (UK £5 million) Series A round. The financing was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing…
Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer CAMBRIDGE, UK, BOSTON and SEATTLE – December 15, 2020 – NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome…
Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increase from baseline of 2.7 g/dL at Week 48, which is equal to the 2.7 g/dL increase seen at Week 16 with pegcetacoplan-treated patients Sustained improvements in transfusion avoidance, reticulocyte count, lactate…
Data were presented at the American Society of Hematology (ASH) Annual Meeting In an analysis from the 16-week Phase 3 PEGASUS study, 70.7% of patients treated with pegcetacoplan compared to 5.1% of eculizumab-treated patients achieved a good, major, or complete hematologic response based on published classifications Quality–of–life substantially improved for pegcetacoplan-treated patients, reaching near-normal levels on several measures, and did not change for eculizumab-treated patients in a PEGASUS analysis at 16 weeks A matching–adjusted indirect…
Leeds, UK, 25 November 2020: LUNAC Therapeutics Ltd (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants with minimal risk of bleeding, announces that it has appointed Carl Sterritt as Chief Executive Officer. Carl has over 25 years of…
Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH) New analyses from the Phase 3 PEGASUS head-to-head study demonstrate greater treatment response and quality–of–life improvements with pegcetacoplan versus eculizumab, a C5 inhibitor Using a matching-adjusted indirect comparison (MAIC), improvements in clinical, hematological and…
Co-led by new investors, Vesalius BioCapital III and BioMedPartners, with participation from all existing investors Funds to be used to advance innovative pipeline based on Topas Particle Conjugates technology platform Lead program TPM203 in clinical development for pemphigus vulgaris Second program, TPM501, progressing towards clinic…